Skip to content
Peptide research

Adamax

Also known as Semax Analog · Adamax Peptide · N-Acetyl Semax Adamantane · NASA
Category
Brain & Cognition
Administration routes
Nasal
Regulatory status
Not FDA-approved

Adamax is a synthetic Semax analog with an added adamantane group for stability, marketed for cognitive enhancement and neuroprotection. The human case is weak: BDNF upregulation and neuroprotection are only low-confidence, and cognitive gains remain speculative. No human safety data exist for Adamax itself, and safety from Semax may not hold for this modified molecule. Not an approved drug in the US; supply is unregulated research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Adamax is an enhanced derivative of Semax, a well-studied Russian neuropeptide used for cognitive enhancement. It adds two chemical modifications — an acetyl group and an adamantane group — to improve its ability to cross the blood-brain barrier, resist enzymatic breakdown, and last longer in the body. These modifications are designed to boost the brain-protective and cognitive-enhancing effects of the parent compound Semax.

How it works in the body

A proposed Semax derivative intended to improve stability and brain delivery. BDNF/TrkB effects were demonstrated for Semax in rats; Adamax's potency, stability, and mechanism remain unverified.

Research overview

Adamax is designed to work by boosting brain-derived neurotrophic factor (BDNF) — a key protein that supports the growth, survival, and plasticity of brain cells. The parent compound Semax has been shown in animal studies to increase BDNF protein levels by 40%, boost BDNF receptor activation by 60%, and triple the expression of certain BDNF genes in the hippocampus (the brain's memory center). A rat study found brain concentrations of particular adamantane–AZT prodrugs 7–18 times those of AZT; this does not establish Adamax uptake. However, it is critical to note that Adamax itself has zero published peer-reviewed studies as of early 2026. All claimed benefits are extrapolated from Semax research and general adamantane pharmacology. Human reports of cognitive benefits are entirely anecdotal. This is a highly experimental compound with an unproven safety and efficacy profile.

Who researches Adamax?

Commonly researched by

  • People researching cognitive enhancement

    Studied for neuroprotective effects, memory, or cognitive performance.

  • People researching bdnf upregulation

    One of the primary studied benefits of Adamax.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(12)

Rated by level of concern

  • No published human safety or toxicology data exists for Adamax specifically

    High

    Literature and trial-registry searches return no Adamax records

  • All safety extrapolations are from the parent compound Semax, which may not fully apply to the modified molecule

    High

    Mechanistic inference; no comparative toxicology published

  • Anecdotal reports of mild headaches and dizziness, typically dose-dependent

    Low

    Anecdotal/community reports only; no primary literature

  • Nasal irritation with intranasal administration

    Low

    Anecdotal; class effect of intranasal peptide formulations

  • Temporary mood or cognition changes during initial use

    Low

    Anecdotal only

  • Insomnia reported when administered late in the day

    Low

    Anecdotal; mechanistic plausibility from ACTH(4-10) analog arousal effects

  • Rare allergic reactions reported anecdotally

    Low

    Class risk for research-grade peptides; no case reports found

  • No long-term safety data available for chronic use

    High

    No published chronic-exposure studies

  • Quality and purity vary among unregulated products sold online; not pharmaceutical-grade manufacturing

    High

    No FDA approval or pharmacopeial standard; research-chemical distribution channel

  • Potential for unknown drug interactions due to lack of formal pharmacological profiling

    Moderate

    No published ADME or interaction profiling

  • Theoretical risk of excessive BDNF signaling with chronic high-dose use (no data to quantify)

    Theoretical

    Mechanistic inference from BDNF/TrkB biology; no Adamax data

  • No established antidote or reversal protocol in case of adverse reaction

    Moderate

    No approved antidote; supportive care only

Interaction summary(7)

Rated by direction with this peptide

  • Monoamine oxidase inhibitors (MAOIs) and other serotonergic/noradrenergic antidepressants

    CautionTheoretical

    ACTH(4-10) analogs including Semax have been reported in rodent work to modulate dopaminergic and serotonergic tone, so additive monoaminergic effects are mechanistically conceivable. No interaction has been demonstrated for Adamax or Semax in humans, and the monoaminergic claim is not established by high-quality indexed evidence.

    Mechanistic inference only; no study of Adamax monoaminergic effects

  • CNS stimulants (amphetamines, methylphenidate, modafinil, high-dose caffeine)

    CautionTheoretical

    Semax is anecdotally and preclinically described as arousal-promoting, and Adamax is marketed on that basis though never measured, so additive overstimulation, anxiety, or insomnia is plausible — consistent with anecdotal reports of insomnia when Adamax is dosed late in the day. No controlled data in any species.

    Mechanistic inference plus anecdotal insomnia reports; no controlled data

  • Standard post-stroke neurorehabilitation (parent-compound context only)

    SynergisticTheoretical

    Semax was given adjunctively alongside rehabilitation in a 110-patient Russian ischemic-stroke study, where plasma BDNF rose and Barthel-index recovery improved (PMID 29798983). That study did not evaluate thrombolysis. Adamax has never been studied in stroke; any synergy is unproven for it.

    PMID 29798983 (Semax plus rehabilitation only; not thrombolysis, not Adamax)

  • Opioid analgesics and enkephalinase-dependent pathways

    CautionTheoretical

    The C-terminal Pro-Gly-Pro moiety is often described as conferring peptidase resistance and possible enkephalinase-related activity, so an additive effect on endogenous or exogenous opioid signaling is conceivable — but this is a low-confidence mechanistic claim, unmeasured for Semax in humans and entirely unmeasured for Adamax.

    Mechanistic inference only; no study of Adamax and enkephalin degradation or opioid signaling

  • Levodopa and dopaminergic agents

    CautionTheoretical

    Overlapping dopaminergic modulation is a theoretical concern based on rodent reports for Semax. The adamantane group is a lipophilic scaffold, not a dopaminergic pharmacophore, and no receptor-binding or shared pharmacology has been demonstrated for the conjugate.

    Mechanistic inference; no receptor-binding or interaction data for Adamax

  • Corticosteroids and the HPA axis

    NeutralLow

    Semax is derived from ACTH(4-10) but is characterized as lacking corticotropic hormonal activity, so meaningful adrenal or corticosteroid interaction is not expected. This has not been verified for the adamantylated analog, but no plausible mechanism for restored corticotropic activity is described.

    Established Semax pharmacology (ACTH(4-10) fragment lacking corticotropic activity); not tested for Adamax

  • Antiepileptic drugs / seizure-threshold-lowering agents

    CautionTheoretical

    Sustained BDNF-TrkB overactivation promotes epileptogenesis in preclinical models, so chronic high-dose use alongside a lowered seizure threshold is a mechanistic worry only — no seizure signal has been reported with Semax or Adamax in humans.

    Mechanistic inference from BDNF/TrkB epileptogenesis literature; no clinical reports

Known risks(12)

  • No published human safety or toxicology data exists for Adamax specifically

  • All safety extrapolations are from the parent compound Semax, which may not fully apply to the modified molecule

  • Anecdotal reports of mild headaches and dizziness, typically dose-dependent

  • Nasal irritation with intranasal administration

  • Temporary mood or cognition changes during initial use

  • Insomnia reported when administered late in the day

  • Rare allergic reactions reported anecdotally

  • No long-term safety data available for chronic use

  • Quality and purity vary among unregulated products sold online; not pharmaceutical-grade manufacturing

  • Potential for unknown drug interactions due to lack of formal pharmacological profiling

  • Theoretical risk of excessive BDNF signaling with chronic high-dose use (no data to quantify)

  • No established antidote or reversal protocol in case of adverse reaction

Drug interactions(5)

  • Anticoagulants/Antiplatelets

    Theoretical/Unknown

    Semax-class peptides affect vascular gene expression and vasodilation; theoretical additive effect with blood thinners. No clinical data available.

  • SSRIs/SNRIs/MAOIs

    Theoretical/Caution advised

    Adamax modulates serotonin, dopamine, and norepinephrine systems. Concurrent use with antidepressants could theoretically produce unpredictable neurotransmitter interactions. No clinical data available.

  • Other nootropics/stimulants

    Theoretical/Unknown

    Using Adamax with other BDNF-enhancing compounds (e.g., Lion's Mane, other Semax analogs) or stimulants may produce additive or unpredictable effects on neuronal excitability.

  • Immunosuppressants

    Theoretical/Caution advised

    Semax research shows significant upregulation of immune response genes (chemokines, immunoglobulins, MHC genes). This could theoretically counteract immunosuppressive therapy.

  • Antihypertensives

    Theoretical/Unknown

    Semax influences vascular tone and vasodilation gene expression. Additive hypotensive effects are theoretically possible.

Research & benefits

Evidence base

Evidence Level
Preclinical
Total Studies
0
Human Studies
0

Adamax has ZERO published peer-reviewed studies as of March 2026. All evidence is extrapolated from extensive Semax research (50+ preclinical studies, several human clinical trials in Russia for stroke therapy) and from general adamantane-modification pharmacology. The parent compound Semax has strong preclinical evidence for BDNF upregulation, neuroprotection, and cognitive effects in animal models, plus human clinical use in Russia/Ukraine for stroke recovery. However, Adamax's specific efficacy, optimal dosing, and safety profile in humans remain entirely unvalidated by published research.

Researched for(6)

Rated by confidence in the evidence

  • BDNF Upregulation

    Low

    Semax rodent studies show BDNF and TrkB increases; no Adamax-specific data exists yet.

    PMID 16996037; PMID 19633950; PMID 29798983 (all Semax, not Adamax)

  • Enhanced Blood-Brain Barrier Penetration

    Speculative

    Mechanism-based only; adamantane conjugation aids CNS delivery but no Adamax uptake data exists.

    No primary source; no Adamax pharmacokinetic literature located

  • Extended Duration of Action

    Speculative

    Mechanism-based only; acetylation may resist degradation, but no Adamax stability data exists.

    No primary source; no published stability or half-life data for Adamax

  • Neuroprotection

    Low

    Semax shows neuroprotection in rodent stroke models and one human trial; no Adamax data.

    PMID 19633950; PMID 29798983 (both Semax)

  • Cognitive Enhancement (Theoretical)

    Speculative

    Semax improved rodent learning; no placebo-controlled trials or any Adamax cognitive data exist.

    PMID 16996037 (Semax rodent avoidance learning only); no Adamax cognitive data

  • Neurotransmitter Modulation

    Speculative

    Proposed from Semax's peptide structure; no receptor-binding or neurochemistry data confirm this for Adamax.

    No primary source; no Adamax receptor or neurochemistry data

Benefits(6)

  • BDNF Upregulation

  • Enhanced Blood-Brain Barrier Penetration

  • Extended Duration of Action

  • Neuroprotection

  • Cognitive Enhancement (Theoretical)

  • Neurotransmitter Modulation

Key studies(5)

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, et al.

    Brain Research

    2006

    Foundational study demonstrating Semax (parent compound) increases BDNF protein 1.4-fold and BDNF mRNA 3-fold in rat hippocampus, establishing the core mechanism Adamax is designed to enhance.

  2. Dolotov OV, Karpenko EA, Seredenina TS, et al.

    Journal of Neurochemistry

    2006

    Demonstrated specific, reversible, calcium-dependent binding of Semax to basal forebrain membranes with rapid BDNF increases at 50-250 mcg/kg doses.

  3. Dmitrieva VG, Povarova OV, Skvortsova VI, et al.

    Cellular and Molecular Neurobiology

    2009

    Showed Semax selectively activates transcription of BDNF, NGF, NT-3, and TrkA/B/C receptors in ischemic rat cortex, demonstrating targeted neuroprotective mechanisms.

  4. Medvedeva EV, et al.

    BMC Genomics

    2014

    Genome-wide analysis revealing Semax affects 96+ genes including immune response, vascular, and neurotrophin pathways in ischemic brain tissue.

  5. Tsuzuki N, Hama T, Kawada M, et al.

    Journal of Pharmaceutical Sciences

    1994

    Established that adamantane conjugation increases brain tissue drug concentrations 7-18x, providing the pharmacological rationale for Adamax's adamantane C-terminal modification.

Regulation & availability

Why researchers look at it

A derivative of Semax with dual chemical modifications (acetyl + adamantane) that are intended to improve brain delivery, but no Adamax uptake increase has been established. The parent compound Semax has 50+ preclinical studies showing 40% increases in BDNF protein levels and 60% boosts in BDNF receptor activation. However, Adamax itself has zero published peer-reviewed studies as of early 2026 — every claimed benefit is extrapolated from Semax data.

FDA status
Not FDA-approved. No Adamax marketing authorization was verified in the US or EU. Semax is a different substance with Russian medicinal authorization. No publicly disclosed Adamax IND was identified; ClinicalTrials.gov does not establish whether an IND exists. Adamax is absent from the reviewed FDA 503A and 503B nomination categories, and no routine bulk-compounding basis was verified. Adamax is not covered by the draft interim compounding policy HHS posted on October 28, 2026, which names only semax free base for nasal use.
WADA status
Adamax is not named. S0 prohibits unapproved pharmacological substances at all times, subject to its criteria. S2 does not prohibit every peptide; obtain compound-specific confirmation.
Prescribability
Not FDA-approved; not approved by any Western regulatory agency. Parent compound Semax is approved in Russia and Ukraine for stroke and cognitive disorders.
Availability
Adamax is not available by prescription anywhere in the world. No routine bulk-compounding basis was verified in the US.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    No regulatory approval in any jurisdiction

Regulatory timeline(6)

  1. 1980s-1990s
    Semax (parent compound) developed at the Institute of Molecular Genetics, Russian Academy of Sciences, Moscow
  2. 2001
    Semax approved in Russia for clinical use in stroke, transient ischemic attack, and cognitive disorders
  3. 2006
    Key studies published demonstrating Semax BDNF/TrkB mechanisms (Dolotov et al., Brain Research; Journal of Neurochemistry)
  4. 2009-2014
    Further Semax mechanistic studies published: neurotrophin transcription activation (2009), genome-wide ischemia analysis (2014)
  5. 2025
    Adamax gains wider recognition in nootropic and biohacking communities. Still no published research.
  6. March 2026 (current)
    Not under FDA review. No publicly disclosed IND identified; filing status cannot be established from public trial searches. No clinical trials registered on ClinicalTrials.gov.

Sources & FAQs

Research sources(5)

  1. PubMed - Dolotov et al. (2006) PMID:16996037 - Semax BDNF/TrkB hippocampal regulation
  2. PubMed - Dolotov et al. (2006) PMID:16635254 - Semax BDNF in basal forebrain
  3. PubMed - Dmitrieva et al. (2009) PMID:19633950 - Semax neurotrophin transcription after ischemia
  4. PubMed/PMC - Medvedeva et al. (2014) PMID:24661604 - Semax genome-wide transcriptional analysis
  5. PubMed - Tsuzuki et al. (1994) PMID:8046599 - Adamantane as brain-directed drug carrier

Frequently asked questions(5)

How is Adamax different from Semax?

Adamax is structurally modified Semax with two additions: an N-acetyl group on the N-terminus (prevents aminopeptidase degradation, enhances BBB penetration) and an adamantane group on the C-terminus (blocks exopeptidase degradation, increases lipophilicity and brain tissue distribution). These modifications are designed to make it more potent and longer-lasting than standard Semax, though this has not been confirmed in published comparative studies.

Are there any published clinical trials on Adamax?

No. As of March 2026, there are zero published peer-reviewed studies on Adamax in any journal. All scientific rationale is extrapolated from extensive Semax research (50+ published studies including human clinical trials in Russia) and from established adamantane-modification pharmacology. All reported human experiences with Adamax are anecdotal.

How is Adamax typically administered?

Adamax is typically administered intranasally, consistent with its parent compound Semax. No standardized dosing has been established through clinical research.

Is Adamax legal?

Regulatory status varies by country. It is not available by prescription anywhere in the world.

What are the risks of using Adamax?

The primary risk is the complete absence of human clinical safety data. Anecdotal reports mention mild headaches, dizziness, nasal irritation, temporary mood changes, and insomnia when taken late in the day. Since there are no published pharmacokinetic, toxicology, or long-term safety studies on Adamax in humans, unknown risks cannot be ruled out. Quality control varies among unregulated products sold online.